Sharp TherapeuticsTSXV:SHRX 15 Current Ratio is 1.06 as of Dec. 2025, which is at its 10-year median of 1.06. GuruFocus rates TSXV:SHRX with a GF Score™ of 15/100. Among 1,410 Biotechnology companies, Sharp Therapeutics ranks worse than 82.77% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Sharp Therapeutics's current ratio for the quarter that ended in Dec. 2025 was 1.06.
Sharp Therapeutics has a current ratio of 1.06. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sharp Therapeutics's Current Ratio or its related term are showing as below:
TSXV:SHRX'
s Current Ratio Range Over the Past 10 Years
Min: 0.06 Med: 1.06 Max: 5.1
Current: 1.06
During the past 3 years, Sharp Therapeutics's highest Current Ratio was 5.10. The lowest was 0.06. And the median was 1.06.
TSXV:SHRX's Current Ratio is ranked worse than 82.77% of 1410
companies
in the Biotechnology industry
Industry Median: 3.89
vs TSXV:SHRX: 1.06
Sharp Therapeutics (TSXV:SHRX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Sharp Therapeutics Current Ratio Related Terms
Sharp Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Sharp Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSXV:SHRX vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Sharp Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sharp Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sharp Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Sharp Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sharp Therapeutics (TSXV:SHRX) has a Current Ratio of 1.06 as of Dec. 2025. This is near median its historical median of 1.06. Over the past decade, Sharp Therapeutics' Current Ratio has ranged from 0.06 to 5.10. According to the industry distribution chart, Sharp Therapeutics ranks #1167 out of 1410 companies in the Biotechnology industry, placing it in the top 82.8%.
Is Sharp Therapeutics' Current Ratio too high?
Sharp Therapeutics' current Current Ratio of 1.06 is near median its 10-year median of 1.06. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 5.10. The Biotechnology industry median Current Ratio is 3.89. Sharp Therapeutics' value of 1.06 is 72.8% below this industry median. Based on the distribution chart, Sharp Therapeutics ranks #1167 out of 1410 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sharp Therapeutics has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Sharp Therapeutics' Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sharp Therapeutics ranks #1167 out of 1410 companies for Current Ratio. This places Sharp Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.89. Sharp Therapeutics' value of 1.06 is 72.8% below this benchmark. Historically, Sharp Therapeutics' own Current Ratio has ranged from 0.06 to 5.10 over the past decade. While the company's 10-year median is 1.06 vs. the industry median of 3.89, Sharp Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sharp Therapeutics's current Current Ratio of 1.06 is 72.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sharp Therapeutics's current Current Ratio is 1.06, which is near median its own 10-year median of 1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sharp Therapeutics stock overvalued right now?
Sharp Therapeutics (TSXV:SHRX) has a current Current Ratio of 1.06. The current Current Ratio is 1.06, which is near median its 10-year median of 1.06 and 72.8% below the Biotechnology industry median of 3.89. Sharp Therapeutics' overall GF Score™ is 15/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Sharp Therapeutics (TSXV:SHRX), the current Current Ratio is 1.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sharp Therapeutics Corp is a preclinical-stage drug discovery company developing therapeutics for genetic diseases. It has developed the patent-protected Disco discovery platform consisting of the CoreX biology, AlloChem chemistry, and Mine computational technologies to discover drugs that selectively activate the protein thats been altered by gene mutation. The company has targeted its discovery engine (Disco) to three hereditary disorders with high unmet need, which include Gauchers Disease, Familial Frontotemporal Dementia, and Niemann Pick Type-C. Its drug development pipeline consists of the following candidates: SEL-148, 721, SEL-148, 742, and SEL-145, 793. Geographically, the company's business operations are carried out in the United States of America.
15GF Score
Get the complete analysis for TSXV:SHRX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:SHRX has been successfully added to your 
